Sunday, August 31, 2014

The Throne......

The Best Room in the House

Saturday, August 23, 2014

That Poop is soooooo Important and deserves a Salute!!!!!


I participated in the Colon Screening Program via direction from my doctor. The program started April 2013. Of course folks have already been doing the stool test way before that.

With every test there are markers, medical range allowed for your results.  My result was Positive for blood in stool, in my case, that is a no brainer.  <50 is the marker, I am 51.  I would say that is the absolute best score one could get.  It is not necessary for me to get a colonoscopy, the doc did say if I chose to want one, then she would send me to my Gastro dude that I see once a year anyways.  My colonoscopy done in 2005 shown no polyps.

Thats it!!!!!

I am fortunate to not have to go thru this program any longer, but there are many British Columbians waiting to hear if they are to get one.  That is what I hear from folks who talk about it. The program is quite insensitive to others who indeed would qualify as they have to WAIT to hear from their health authority. Last heard 16 weeks just to receive a call and assess the score, history and if necessary the appointment.

The Importance of Watching what you dump into the Toilet

Cannot stress this enough, always look at what you leave behind.  Early detection of anything gives you a fighting chance.  There is always the Emergency Department at your local hospital should your bowel movement scare you enough to bother the folks on the phone than going in.  I opt for waiting 10 hours than 16 weeks .....

Thursday, July 24, 2014

FIT results and

Performed the FIT test and within 2 days I received my results through the website.  It showed I am positive which in medical land could mean a lot of things.  Since I have Crohns/Ulcerative Colitis, this in my mind, would be standard results.

By going through this new program, I should receive a letter, possibly 2 weeks, showing what I already know and that a Patient Care Co-ordinator will call me to discuss results and such, that has been UPGRADED TO 10 WEEKS NOW.

I had on the lab requistion that my doctor and Gastro dude be notified of the results.

What I am thinking and probably will find out later is that, folks like us, should be doing a different test, as we already will show blood in our stools.  But hey if there are other signs showing Cancer, I am all ears.

Interested in my ehealth?

 ArrowAbout Us
ArrowContact Us
ArrowView Demo 

Am I eligible to use my ehealth?

To register you must:

  • Be age 16 or older, or have received a Welcome Letter from Excelleris
  • Have a BC Care Card number
  • Have had lab work within the last 30 days at:
    • Lifelabs, Valley Medical Laboratories, BC Biomedical Laboratories or
    • As an outpatient only at Vancouver Coastal Health or Providence Health Care

I give this website a thumbs up.  Follow the guidelines above and register.  You get your blood work results, urine sample results, stool sample results, and the end of the day you went to the lab, with the exception of certain tests, like stool. Chemistry tests take an extra day or so.

You have to be a level headed individual to sign up to this health site,  You know what they say KNOWLEDGE IS POWER. well that applies if you are a mature person who does not go into DEFCON 4, in an instant.  If you are that type of person, do not register and sign up. Leave it in your Doctors hands.

Friday, July 11, 2014

Colon Screening in BC

Colon screening has ramped up here in BC, or either that I have come to the age where I qualify for testing.

That said, I was diagnosed with Crohns and Ulcerative Colitis in 2005, have had only one colonoscopy, and that was during the prognosis/diagnosis stage of my diseases.  I have had only 3 stool tests since my 2005 diagnosis.  The most recent upgrade of stool testing is the FIT test, Fecal Immunochemical Test.

The current program is as follows, your health care practitioner, specialist, family physician will write a Lab requisition for you to collect the FIT kit from your local laboratory, you then perform the test in the comfort of your home.

My first attempt failed as the paper sheet that is to float on the water did not do a good job and my sample was then contaminated.  So I shall resort to more drastic measures which I will refrain from sharing, but I will follow the guidelines as to not contaminate the sample.  Return your completed sample to your Laboratory. Results do take some time.

A result letter is mailed to you and advises you that a Program Coordinator will contact you in a few weeks, to discuss the findings.  That may upset a few patients depending on their family history, what they are experiencing and seeing in their stool, etc.  There are no calming ways to help patients.  However, there are other folks in the Health Authority to assist and relieve some stress for the patient.  Check link below for more information.

Click on link below for more information from the BC Cancer Agency

To tell or not to tell 24Hours Toronto

Click link below for full story our employers have the right to know

Thursday, July 3, 2014

Crohn's sufferer pursues dream of being a model after bikini photo exposing colostomy bags becomes an internet sensation

  • Confident, courageous.  A young lady not letting the chronic disease bring her spirit down.
  • Click on link below for her story and more photos.

  • The photo of Bethany Townsend, 23, from Worcester, has been viewed by more than nine million people and has received 190,000 likes on Facebook
  • Positive feedback has given her the confidence to become a model
  • Mrs Townsend hopes to inspire other people with Crohn's disease to feel comfortable in their skin and raise awareness of the condition
  • She was fitted with two colostomy bags in 2010 and since then has undergone a stem cell transplant when she caught MRSA and nearly died
  • Her Crohn's is still active leaving her the option of having a bowel transplant 

Read more:
Follow us: @MailOnline on Twitter | DailyMail on Facebook

Sunday, June 29, 2014

Jeff Leach --His basic message: to increase and diversify your plant intake. The foods you pick should be chewy, should get stuck in your teeth." "Eat the end of the asparagus, the stalk of the broccoli.

JEFF LEACH scientist 
"has uncovered a metropolis of microbes living in our guts.  These little bugs might be the cornerstone of great health and have the potential to improve our weight, mood, allergies, heart health and more."

This man deserves an honorable mention in my blog as he explores the microbes living in our guts.  The latest "Eatingwell Magazine, July/August 2014" writes his story and journey.  Research on the gut microbiome has exploded over the past few years.  This bold new frontier may just provide the string theory of all human disease.  
The Wild World Within
Written by Gretel H Schueller
Eatingwell Magszine July/August 2014 issue

Excerpts from the magazine, "Yogurt delivers beneficial bacteria.  But this Leek could be even more powerful."

"The human body is actually only about 25% human cells -- most of our cells are bacterial."

"The human gut holds about 3 pounds of bacteria and more than 1000 different species."

"More than 7,000 people have already joined in on the worlds largest public microbiome project:

"Numerous studies also show that scrubbing away our microbes may be weakening our bodies natural defenses--something Leach has experienced firsthand:  12 years ago at age 2, his daughter was diagnosed with Type 1 diabetes, an autoimmune disease.  "My daughter was born C-section --Strike 1, breastfed very short --Strike 2, she received antibiotics at a very young age--Strike 3, and she lived in an environment where we basically wet-wiped everything and bathed her twice a day--Strike 4."  Leach feels strongly that her disease is a by-product of our culture.

"Leach is doing informal tests on himself.  Since January 1, 2014, he has been trying out different diets: fermented foods, vegan, raw food, Paleo and others.  He is following each one for 10 to 12 days, collecting daily stool samples.  By "whacking his microbiome around" he hopes to zero in on the kety foods that fuel the good and bad players of the gut. "


Bananas, garlic, onions, chicory root, wheat, leeks, asparagus, artichokes and garlic contain naturally occurring fructans. Eating these foods will help you increase your fructan intake as well as the amount of overall fiber you get in your diet, since these foods also contain other types of fiber as well as fructans.
Watch for ingredients label for oligosaccharides, fructooligosaccharides, FOS, scFOS, inulin or any form of chicory to determine which foods contain added fructans. Even foods you may not expect to contain much fiber, such as beverages and ice creams, may contain added fructans
"Leach believes we should already feel empowered.  His basic message: to increase and diversify your plant intake.  The foods you pick should be chewy, should get stuck in your teeth."  "Eat the end of the asparagus, the stalk of the broccoli.  Become a little more adventurous in the produce section."
A study done at the Massachusetts General Hospital with over 1,500 people have shown Crohn's patients given a PREbiotic fiber supplement (not Probiotic) each day, has shown the disease symptoms have decreased significantly.

His latest book

Jeff Leach, founder of the Human Food Project 


Saturday, June 21, 2014

For intimate healthcare needs.....

Making life easier

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.
Our business includes ostomy care, urology and continence care, and wound and skin care. We operate globally and employ more than 8,500 people.  Learn more about us.

Wednesday, May 21, 2014

FDA Approves Entyvio (vedolizumab) to treat Ulcerative Colitis and Crohn's Disease

May 20, 2014 -- The U.S. Food and Drug Administration today approved Entyvio (vedolizumab) injection to treat adult patients with moderate to severe ulcerative colitis and adult patients with moderate to severe Crohn‘s disease.
Entyvio is approved to treat those conditions when one or more standard therapies (corticosteroids, immunomodulators, or tumor necrosis factor blocker medications) have not resulted in an adequate response.
Ulcerative colitis is a chronic disease that affects about 620,000 Americans. It causes inflammation and ulcers in the inner lining of the large intestine and is one of two main forms of chronic inflammatory bowel disease. The inflammation can lead to abdominal discomfort, gastrointestinal bleeding, and diarrhea.
Crohn‘s disease is a chronic inflammatory condition that causes inflammation, or swelling, and irritation of any part of the digestive tract—also called the gastrointestinal (GI) tract. More than a half million Americans have been diagnosed with Crohn‘s disease.
“Ulcerative colitis and Crohn‘s disease are debilitating diseases that impact the quality of life of those who have these conditions,” said Amy G. Egan, M.D., M.P.H., acting deputy director of the Office of Drug Evaluation III in the FDA‘s Center for Drug Evaluation and Research. “Although there is no cure for these conditions, today‘s approval provides an important new treatment option for patients who have had an inadequate response to conventional therapy to help control their symptoms.”
The safety and effectiveness of Entyvio for ulcerative colitis were established in two clinical trials involving approximately 900 patients who had not responded adequately to corticosteroids, immunomodulators, or tumor necrosis factor blocker medications. Evaluations of patients included measures of stool frequency, rectal bleeding, endoscopic findings and a physician‘s overall assessment.
Results showed that a greater percentage of participants treated with Entyvio compared to a placebo achieved and maintained clinical response, achieved and maintained clinical remission, achieved corticosteroid-free clinical remission, and as seen during endoscopy, had improved appearance of the colon.
The safety and effectiveness of Entyvio for Crohn‘s disease were established in three clinical trials involving approximately 1,500 patients who had not responded adequately to corticosteroids, immunomodulators, or tumor necrosis factor blocker medications. Results showed that a greater percentage of participants treated with Entyvio compared to a placebo achieved clinical response, achieved clinical remission, and achieved corticosteroid-free clinical remission.
Entyvio is an integrin receptor antagonist. Integrin receptors are proteins expressed on the surface of certain cells. Integrin receptors function as bridges for cell-cell interactions. Entyvio blocks the interaction of a specific integrin receptor (expressed on circulating inflammatory cells) with a specific protein (expressed on cells in the interior wall of blood vessels), and thereby blocks the migration of those circulating inflammatory cells across those blood vessels and into areas of inflammation in the gastrointestinal tract. The most common side effects in patients treated with Entyvio include headache, joint pain, nausea, and fever. The most serious risks associated with Entyvio include serious infections, hypersensitivity and infusion-related reactions; and hepatotoxicity.
Another type of integrin receptor antagonist has been associated with progressive multifocal leukoencephalopathy (PML), a rare and often fatal opportunistic infection of the central nervous system. PML is caused by a virus and typically only occurs in patients whose immune systems are compromised. There were no cases of PML identified among Entyvio clinical trial participants
In Entyvio clinical trials, participants were actively monitored for PML with frequent and regular screenings, and evaluations of any new, unexplained neurological symptoms, as necessary. Because clinical trials are conducted under tightly controlled conditions, adverse reaction ratesobserved in the clinical trials of a drug may not reflect the rates that might be observed in practice. Therefore, while there were no cases of PML seen among patients participating in Entyvio clinical trials, there remains uncertainty regarding the risk of PML in patients taking Entyvio.
Health care professionals should monitor patients on Entyvio for any new onset, or worsening, of neurological signs and symptoms. The FDA will continue to work with the sponsor to further investigate the risk of PML through a required post-marketing study and enhanced, expedited adverse event reporting.
Consumers and health care professionals are encouraged to report adverse reactions from the use of Entyvio to the FDA‘s MedWatch Adverse Event Reporting program at or by calling 1-800-FDA-1088.
Entyvio is marketed by Deerfield, Ill.-based Takeda Pharmaceuticals America, Inc.
Source: FDA
Posted: May 2014

Thursday, April 17, 2014

Vancouver General Hospital

Vancouver General Hospital
700 West 10th Avenue
Jim Pattison Pavilion 2nd Floor
Lauener Room
Sassafras Cafeteria

Discussion on Crohn's Disease

Open meetings to the General Public
Last Thursday of every month
7:00 P.M. to 9:00 P.M

Monday, March 24, 2014


From our friends at Healthy Holistic Living we present to you the Poop Chart.  It is all about color and shape.  Based on the chart I am a Type 4 and 5.  So I am the ultimate miracle pooper with Crohns and Colitis.  Check out their article for more information:

Thursday, March 20, 2014

Clinical Trials for Ulcerative Colitis.........Read more inside



Patients are needed to participate in a clinical research study of GS-5745 and Placebo to evaluate Ulcerative Colitis


Patients are needed to participate in a clinical research study of GS-5745 and Placebo to evaluate Ulcerative Colitis
A Phase 1 Double-blind, Randomized, Placebo-Controlled, Staggered, Single and Multiple Ascending Dose, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 in Subjects With Moderate to Severe Ulcerative Colitis
This is a staggered, placebo-controlled, single and multiple ascending dose (SAD/MAD) study evaluating the safety, tolerability and pharmacokinetics of GS-5745 in patients between ages of 18 to 65 years with moderate to severe ulcerative colitis. This study will provide valuable data that can help establish the safety, pharmacokinetics and efficacy of GS-5745 in ulcerative colitis patients.

For more information click on link below for contact information and locations